ARCT
Arcturus Therapeutics Holdings Inc.
$9.84
-8.29%
2026-10-23
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-3.82
EPS (TTM)
$-3.33
ROE
-46.3%
Revenue Growth (YoY)
-89.5%
Profit Margin
0.0%
Debt/Equity
13.35
Price/Book
2.29
Beta
2.48
Market Cap
$393.7M
Avg Volume (10D)
929K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$17.96
60D Low
$5.64
Avg Volume
987K
Latest Close
$9.84
Get breakout alerts for ARCT
Sign up for Breakout Scanner to receive daily notifications when ARCT triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Arcturus Therapeutics Holdings Inc. (ARCT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ARCT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ARCT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.